Qsemble Capital Management LP Acquires New Stake in Qiagen (NYSE:QGEN)

Qsemble Capital Management LP bought a new stake in shares of Qiagen (NYSE:QGEN) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 103,244 shares of the company’s stock, valued at approximately $4,705,000. Qiagen accounts for 0.9% of Qsemble Capital Management LP’s portfolio, making the stock its 21st biggest position.

Several other institutional investors also recently bought and sold shares of QGEN. GAMMA Investing LLC raised its stake in shares of Qiagen by 806.5% in the third quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock valued at $26,000 after acquiring an additional 500 shares in the last quarter. Toronto Dominion Bank purchased a new stake in shares of Qiagen in the 2nd quarter valued at approximately $27,000. Massmutual Trust Co. FSB ADV raised its holdings in shares of Qiagen by 39.8% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock valued at $39,000 after purchasing an additional 243 shares in the last quarter. CWM LLC lifted its position in shares of Qiagen by 12.0% during the 2nd quarter. CWM LLC now owns 2,505 shares of the company’s stock worth $103,000 after purchasing an additional 269 shares during the last quarter. Finally, Headlands Technologies LLC grew its stake in shares of Qiagen by 396.6% during the second quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock worth $113,000 after purchasing an additional 2,189 shares in the last quarter. 70.00% of the stock is owned by institutional investors and hedge funds.

Qiagen Price Performance

Qiagen stock traded up $0.41 during midday trading on Monday, reaching $43.19. 96,886 shares of the company were exchanged, compared to its average volume of 1,157,184. The firm’s 50-day simple moving average is $43.43 and its 200-day simple moving average is $43.73. Qiagen has a 1 year low of $39.03 and a 1 year high of $47.44. The company has a market capitalization of $9.86 billion, a price-to-earnings ratio of 109.69, a P/E/G ratio of 3.32 and a beta of 0.41. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.89 and a current ratio of 2.17.

Analyst Ratings Changes

A number of equities analysts recently issued reports on QGEN shares. Hsbc Global Res raised Qiagen to a “hold” rating in a report on Thursday, October 17th. Robert W. Baird upped their price objective on shares of Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Finally, HSBC cut Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price objective for the company. in a research note on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $50.88.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.